<DOC>
	<DOC>NCT00596817</DOC>
	<brief_summary>This study will evaluate the efficacy of Vortioxetine in the prevention of relapse of major depressive episodes in patients who responded to open-label treatment with Vortioxetine.</brief_summary>
	<brief_title>Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>Major Depressive Episode (MDE) as the primary diagnosis according to DSMIV TR criteria At least one other MDE before the current one Moderate to severe depression Any current psychiatric disorder other than Major Depressive Disorder (MDD) as defined in the DSMIV TR Any substance disorder within the previous 6 months Female patients of childbearing potential who are not using effective contraception Use of any psychoactive medication 2 weeks prior to screening and during the study Randomisation Criteria: Patients in remission (MADRS total score &lt;=10) at both Week 10 and Week 12 Other protocoldefined inclusion and exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Relapse prevention</keyword>
	<keyword>Antidepressants</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Multicentre study</keyword>
</DOC>